Company news

Cogent Biosciences, Inc. news in 2020

Cogent Biosciences, Inc.'s news releases, calls and decks from 2020, newest first.

View company

Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriter's Option to Purchase Additional Shares

December 3, 2020

Cogent Biosciences Appoints Brad Barnett as Chief Technology Officer

November 29, 2020

Cogent Biosciences Announces $60.0 Million Public Offering of Shares of Common Stock

November 29, 2020

Cogent Biosciences to Participate in 3rd Annual Evercore ISI HealthCONx Virtual Conference

November 19, 2020

Cogent Biosciences Announces Final Results from PLX9486 Phase 1/2 Study in Advanced GIST Patients at CTOS 2020

November 17, 2020

Cogent Biosciences to Present at Jefferies 2020 Virtual London Healthcare Conference

November 11, 2020

Cogent Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Updates

November 8, 2020

Cogent Biosciences to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference

November 4, 2020

Cogent Biosciences Appoints Andrew Robbins as Chief Executive Officer

October 25, 2020

Unum Therapeutics Announces Company Name Change to Cogent Biosciences, Highlights Recent Scientific and Operational Progress

October 4, 2020

Unum Therapeutics Transfers BOXR Cell-Based Therapy Technology to SOTIO

August 30, 2020

Unum Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Updates

August 10, 2020

Unum Therapeutics Inc. Announces Acquisition of Kiq LLC

July 5, 2020

Unum Therapeutics Reports First Quarter Financial Results and Provides Corporate Updates

May 10, 2020

Unum Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Updates

March 25, 2020

Unum Therapeutics Announces Common Stock Purchase Agreement for up to $25 Million with Lincoln Park Capital

March 19, 2020

Unum Therapeutics Implements Strategic Restructuring to Prioritize Efforts on BOXR1030 for the Treatment of Solid Tumor Cancers

March 1, 2020

Unum Therapeutics Provides Updates to its Phase 1 Trial of ACTR707 for HER2+ Solid Tumor Cancers

January 28, 2020

Decks in 2020